World Pharma Today

  Noah Nasser, CEO of  datma Most pharmaceutical companies have already invested heavily in real-world data (RWD). These internal datasets, often curated over years, serve as the foundation for ongoing research and analysis. They often represent significant investment in time, budget, and coordination across internal teams and systems. But even robust internal datasets can fall short when new analytical needs or questions arise, particularly in the context of targeted therapies where biomarker specific insights are essential.  When a stakeholder asks a question about a subpopulation defined by a biomarker, mutation type, or clinical context, the existing dataset may not contain the patients needed to answer it. The missing data might be subtle, such as biomarker status or specific genomic features, but they are often essential. This doesn’t mean the internal dataset is flawed, it reflects the evolving nature of oncology and the reality that new questions often demand new ...

default Pharma teams can now assess biomarker coverage across datma’s federated network with no cost, contracts, or IT support required. datma, a leader in federated real-world data access, today announced the launch of the Federated Biomarker Explorer, a new application that allows pharmaceutical teams to evaluate real-world biomarker coverage across datma’s federated network of participating data contributors before entering into a formal data partnership. This tool is designed to help teams answer a critical question early in the data sourcing process: Does this dataset contain the patient populations we need? The Federated Biomarker Explorer provides aggregate, cohort-level visibility into biomarker presence across the datma federated network. Teams can filter by a range of clinical and demographic attributes to assess feasibility. No data integration, procurement involvement, or internal IT support is required, making the application immediately accessible for teams looking to val...